ALMIRALL overview

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results. Financial highlights (€ rounded million) H1 2023 H1 2022 Variation Net Sales 466.1 436.6 6.8% Total EBITDA 101.3 107.6 -5.9% Net Income 12.0 27.3 -56.0% Normalized Net Income 11.6 27.6 -58.0% Summary of results Net Sales reached €466.1 MM, a +6.8% year-on-year increase boosted by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri ® (tildrakizumab) significantly improved wellbeing in patients with moderate-to-severe plaque psoriasis achieving a wellbeing status similar to the general population 1 after 16 weeks, which was maintained up to week 28 ¡Error! Marcador no definido. . These first results of the POSITIVE study were presented in a poster at the 25 th World Congress of Dermatology, held in...

Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of people living with psoriatic disease believe that it negatively affects their daily activities, causing a heavy physical, emotional and social burden that affects their mental health 1 and wellbeing 2 . Despite its high prevalence - approximately 1.52% of the UK population (1.01 million people estimated)...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital increase announced yesterday evening (the “ Capital Increase ”) following completion of the accelerated book-building offering, which was carried out by J.P. Morgan and BNP PARIBAS as Joint Global Coordinators and Joint Bookrunners. As a result of the Capital Increase, the Company has raised a...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “ Capital Increase ”) for a total aggregate amount (including nominal value and share issue premium) of approximately EUR 200,000,000 by issuing new ordinary shares of the Company belonging to the same class and series as the outstanding shares (the “ New Shares ”) in consideration for cash contributions. The...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results. Financial highlights (€ rounded million) Q1 2023 Q1 2022 Variation Net Sales 232.0 218.8 6.0% Total EBITDA 51.8 59.6 (13.1%) Net Income 7.7 20.4 (62.3%) Normalized Net Income 7.7 20.5 (62.4%) Summary of results Net Sales reached €232.0 MM, a +6% year-on-year increase underpinned by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab’s stable and long-lasting results at one year of treatment in...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, placebo-controlled, parallel-group, Phase 3 studies (NCT04146363 and NCT04178967), evaluating lebrikizumab as monotherapy in adult and...